Innoviva

#Long-Acting Oral Therapeutics #Critical Care #Infectious Disease #Specialty Pharma

Innoviva Inc. (NASDAQ: INVA) is a specialty pharmaceutical company with a diversified portfolio of marketed therapeutics and a growing focus on long-acting drug delivery. The company is reviving the Lyndra Therapeutics long-acting oral drug platform, originally developed at Bob Langer's MIT lab, with Langer and Janet Woodcock as senior advisors.

Company Info

Sector:Pharmaceutical / Specialty Therapeutics & Drug Delivery

Headquarters:Waltham, Massachusetts, USA

Founded:2000

Website:www.innoviva.com/

Upcoming Milestones & Key Dates

2026-06-18

Corporate

Lyndra platform revival announcement

2026-Q4

R&D

Lyndra lead program candidate selection

2027-H1

Regulatory

Potential first Lyndra-program IND filing

Clinical Development Pipeline

Lyndra Long-Acting Oral Platform

Target: Long-acting oral dosage form

Multiple chronic indications (TBD)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Innoviva Specialty Therapeutics Portfolio

Target: Multiple approved assets

Critical care and infectious disease

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Xerava (eravacycline)

Target: Tetracycline antibiotic

Complicated intra-abdominal infections

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Innoviva, Inc. (INVA) Launches Nortiva Bio to Advance Long-Acting Oral Therapies ↗

Innoviva, Inc. (INVA) Launches Nortiva Bio to Advance Long-Acting Oral Therapies.

Leadership Team

Mark Chin

Chief Executive Officer

Jennifer Ziegler

Chief Operating Officer

Robert Langer

Senior Advisor (Lyndra platform)

Careers & Job Openings

See all open roles

Multiple Departments

See careers page

Apply Now →